Mikafungin Teva (Micafungin)

• Micafungin is an echinocandin antifungal that inhibits fungal cell wall synthesis and is approved for several serious Candida infections.
• Invasive candidiasis: treats bloodstream and deep‑tissue Candida infections, including candidemia and candidal endocarditis, in adult and pediatric patients.
• Esophageal candidiasis: clears Candida infection of the esophagus, relieving pain and dysphagia in immunocompromised individuals.
• Prophylaxis in hematopoietic stem cell transplantation: prevents Candida infections during the neutropenic phase of transplantation, reducing incidence of invasive disease.

• Micafungin binds to the catalytic subunit of β‑(1,3)‑D‑glucan synthase, an enzyme essential for synthesis of β‑(1,3)‑D‑glucan, a key structural component of the fungal cell wall. Inhibition of this enzyme disrupts cell wall integrity, leading to osmotic instability and fungal cell death. The drug exhibits fungicidal activity against most Candida species and limited activity against Aspergillus spp. Its selective action spares human cells because mammalian cells lack β‑(1,3)‑D‑glucan synthase.

Micafungin may cause a range of adverse reactions, from mild infusion‑related events to rare serious conditions.

Common Side Effects

• Infusion‑related reactions: flushing, chills, or fever.
• Nausea or vomiting.
• Elevated liver enzymes (ALT/AST).
• Headache.

Serious or Rare Side Effects

• Severe hepatic failure or hepatitis.
• Anaphylaxis or severe allergic reaction.
• Stevens‑Johnson syndrome/toxic epidermal necrolysis.
• Acute renal impairment.

When using Micafungin, clinicians should observe several safety considerations to minimize risk.

• Renal function: monitor serum creatinine and urine output, especially in patients with pre‑existing kidney disease.
• Hepatic function: assess baseline liver enzymes and repeat monitoring during therapy.
• Concomitant antifungal therapy: avoid overlapping use with other echinocandins or high‑dose azoles unless clinically justified.
• Pregnancy and lactation: use only if the potential benefit outweighs the potential risk to the fetus or infant.
• Drug interactions: review all concomitant medications for possible pharmacokinetic interactions.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, affecting its concentration or increasing toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise micafungin plasma levels, increasing toxicity risk.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower micafungin exposure, reducing efficacy.
• Co‑administration with other echinocandins: additive toxicity, not recommended.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole, voriconazole): possible additive antifungal effect, monitor liver function.
• Immunosuppressants (e.g., tacrolimus, cyclosporine): may require dose adjustment, monitor drug levels.
• Statins (e.g., simvastatin): increased risk of myopathy, observe for muscle symptoms.